The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin: A propensity score matched analysis
Open accessAbstract
Summary: In addition to warfarin, there are four non-vitamin K antagonist oral anticoagulants (NOACs) available for stroke prevention in non valvular atrial fibrillation (NVAF). There are limited data on the comparative risks of major bleeding among newly anticoagulated NVAF patients who initiate warfarin, apixaban, dabigatran, or rivaroxaban, when used in ‘real world’ clinical practice. The study used the Truven MarketScan® Commercial & Medicare supplemental US claims database. NVAF patients aged ≥18 years newly prescribed an oral anticoagulant 01JAN2013–31DEC2014, with a ≥1-year baseline period, were included (study period: 01JAN2012–31DEC2014). Major bleeding was defined as bleeding requiring hospitalisation. Propensity score matching (PSM) was used to balance age, sex, region, baseline comorbidities, and comedications. Cox proportional hazards models were used to estimate the PSM hazard ratio (HR) of major bleeding. Among 45,361 newly anticoagulated NVAF patients, 15,461 (34.1 %) initiated warfarin, 7,438 (16.4 %) initiated apixaban, 17,801 (39.2 %) initiated rivaroxaban, and 4,661 (10.3 %) initiated dabigatran. Compared to matched warfarin initiators, apixaban (HR: 0.53; 95 % CI: 0.39–0.71) and dabigatran (HR: 0.69; 95 % CI: 0.50–0.96) initiators had a significantly lower risk of major bleeding. Patients initiating rivaroxaban (HR: 0.98; 95 % CI: 0.83–1.17) had a non-significant difference in major bleeding risk compared to matched warfarin patients. When comparisons were made between NOACs, matched rivaroxaban patients had a significantly higher risk of major bleeding (HR: 1.82; 95 % CI: 1.36–2.43) compared to apixaban patients. The differences for apixaban-dabigatran and dabigatran-rivaroxaban matched cohorts were not statistically significant. Among newly anticoagulated NVAF patients in the real-world setting, apixaban and dabigatran initiation was associated with significantly lower risk of major bleeding compared to warfarin initiation. When compared to apixaban, rivaroxaban initiation was associated with significantly higher risk of major bleeding. Note: The review process for this paper was fully handled by Christian Weber, Editor in Chief. Supplementary Material to this article is available online at www.thrombosis-online.com.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290 · cited 1×
“The findings remained consistent with the main analysis and inpatient death did not have an impact on the results (24, 25).”
ResultAustin, P. C. (2011) · Multivariate Behavioral Research · doi:10.1080/00273171.2011.568786 · Cited by 12,242 · cited 1×
“In the RE-LY trial, the rate of major bleeding was 3.36 % per year for warfarin, compared to 2.71 % per year (HR: 0.80; 95 % CI: 0.69–0.93; p=0.003) for 110 mg BID and 3.11 % per year (HR: 0.93; 95 % CI: 0.81–1.07; p=0.31) for 150 mg BID dabigatran (12).”
InfluentialDabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000041 · Cited by 7,115
Ruff, C. T., Giugliano, R. P., Braunwald, E., Hoffman, E. B., Deenadayalu, N., Ezekowitz, M. D., Camm, A. J., Weitz, J. I., Lewis, B. S., Parkhomenko, A., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62343-0 · Cited by 5,051 · cited 3×
“To overcome the limitations of VKAs, the non-VKA oral anti-coagulants (NOACs) have been introduced and offer relative efficacy, safety, and convenience compared to VKA therapy (7).”
BackgroundInfluential2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.022 · Cited by 2,955
Introduction to the Analysis of Survival Data in the Presence of Competing Risks
Austin, P. C., Lee, D. S., & Fine, J. P. (2016) · Circulation · doi:10.1161/circulationaha.115.017719 · Cited by 2,653
Atrial Fibrillation: A Major Contributor to Stroke in the Elderly: The Framingham Study
Wolf, P. A. (1987) · Archives of Internal Medicine · doi:10.1001/archinte.1987.00370090041008 · Cited by 1,108 · cited 1×
“Atrial fibrillation (AF) increases the risk of ischaemic stroke by five-fold and is associated with 15 % of strokes for all age groups and 30 % in persons over the age of 80 years (1).”
BackgroundUnderuse of Oral Anticoagulants in Atrial Fibrillation: A Systematic Review
Ogilvie, I. M., Newton, N., Welner, S. A., Cowell, W., & Lip, G. Y. H. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.11.025 · Cited by 927
Self-citationGraham, D. J., Reichman, M. E., Wernecke, M., Zhang, R., Southworth, M. R., Levenson, M., Sheu, T.-C., Mott, K., Goulding, M. R., Houstoun, M., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.012061 · Cited by 644
Camm, A. J., Amarenco, P., Haas, S., Hess, S., Kirchhof, P., Kuhls, S., van Eickels, M., & Turpie, A. G. G. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv466 · Cited by 452
Larsen, T. B., Skjøth, F., Nielsen, P. B., Kjældgaard, J. N., & Lip, G. Y. H. (2016) · BMJ · doi:10.1136/bmj.i3189 · Cited by 441
Self-citationToo Much Ado about Propensity Score Models? Comparing Methods of Propensity Score Matching
Baser, O. (2006) · Value in Health · doi:10.1111/j.1524-4733.2006.00130.x · Cited by 372
Husted, S., Wallentin, L., Andreotti, F., Arnesen, H., Bachmann, F., Baigent, C., Huber, K., Jespersen, J., Kristensen, S. D., Lip, G. Y. H., et al. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-06-0443 · Cited by 365
Self-citationHusted, S., Wallentin, L., Andreotti, F., Arnesen, H., Bachmann, F., Baigent, C., Huber, K., Jespersen, J., Kristensen, S., Lip, G. Y. H., et al. (2013) · Thrombosis and Haemostasis · doi:10.1160/th12-06-0403 · Cited by 364
Self-citationAn automated database case definition for serious bleeding related to oral anticoagulant use
Cunningham, A., Stein, C. M., Chung, C. P., Daugherty, J. R., Smalley, W. E., & Ray, W. A. (2011) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2109 · Cited by 359
Dabigatran and Postmarketing Reports of Bleeding
Southworth, M. R., Reichman, M. E., & Unger, E. F. (2013) · New England Journal of Medicine · doi:10.1056/nejmp1302834 · Cited by 353
Abraham, N. S., Singh, S., Alexander, G. C., Heien, H., Haas, L. R., Crown, W., & Shah, N. D. (2015) · BMJ · doi:10.1136/bmj.h1857 · Cited by 347
Lip, G. Y. H., Larsen, T. B., Skjøth, F., & Rasmussen, L. H. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.03.019 · Cited by 288
Self-citationAdjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation
Hart, R. G., Pearce, L. A., & Aguilar, M. I. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-8-200710160-00018 · Cited by 173
An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation
Ansell, J., & Mantha, S. H. (2012) · Thrombosis and Haemostasis · doi:10.1160/th12-02-0093 · Cited by 157
Bykov, K., Bartels, D. B., Huybrechts, K. F., Zint, K., Schneeweiß, S., & Seeger, J. D. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-06-0497 · Cited by 136
Propensity Score Methods for Creating Covariate Balance in Observational Studies
Pattanayak, C. W., Rubin, D. B., & Zell, E. R. (2011) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2011.06.008 · Cited by 111
Pattanayak, C. W., Rubin, D. B., & Zell, E. R. (2011) · Revista Española de Cardiología · doi:10.1016/j.recesp.2011.06.008 · Cited by 110
Savelieva, I., Bajpai, A., & Camm, A. J. (2007) · Annals of Medicine · doi:10.1080/07853890701320662 · Cited by 106
Ho, C. W., Ho, M.-H., Chan, P., Hai, J. J., Cheung, E. H.-L., Yeung, C., Lau, K. K., Chan, K., Lau, C., Lip, G. Y. H., et al. (2014) · Stroke · doi:10.1161/strokeaha.114.006476 · Cited by 98
Self-citation
Cited by
January, C. T., Wann, L. S., Calkins, H., Chen, L. Y., Cigarroa, J. E., Cleveland, J. C., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., Furie, K. L., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000665 · Cited by 2,744
January, C. T., Wann, L. S., Calkins, H., Chen, L. Y., Cigarroa, J. E., Cleveland, J. C., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., Furie, K. L., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.01.011 · Cited by 2,205
Steffel, J., Verhamme, P., Potpara, T. S., Albaladejo, P., Antz, M., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy136 · Cited by 2,123
Self-citationYao, X., Shah, N. D., Sangaralingham, L. R., Gersh, B. J., & Noseworthy, P. A. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.03.600 · Cited by 467
January, C. T., Wann, L. S., Calkins, H., Chen, L. Y., Cigarroa, J. E., Cleveland, J. C., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., Furie, K. L., et al. (2019) · Heart Rhythm · doi:10.1016/j.hrthm.2019.01.024 · Cited by 404
Metadata
- Authors
- Keshishian, A., Kamble, S., Pan, X., Mardekian, J., Horblyuk, R., Hamilton, M., & Lip, G. Y. H.
- Venue
- Thrombosis and Haemostasis
- Publisher
- Georg Thieme Verlag KG
- Published
- 2016-09
- Volume
- 116
- Issue
- 11
- Pages
- 975-986
- ISSN
- 0340-6245 (ISSN-L)
- 2567-689X
- OpenAlex
- W2520573665
- Cited by
- 262
- References
- 28
- FWCI
- 42.08
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.